Leslie Recio

Leslie Recio

Auto-generated profile, based on publicly available information

Leslie Recio

ScitoVation, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in Mutagenesis
Verified
Journal Article
Open access
ASAnn-Marie Steen
Ann-Marie Steen
KMKathy G. Meyer
Kathy G. Meyer
LRLeslie Recio
Leslie Recio
1,3-Butadiene (BD) is an indirect-acting mutagen that is bioactivated in laboratory animals to at least two mutagenic metabolites, 1,2-expoxy-3-butene (EB) and 1,2,3,4-diepoxybutane (DEB). In the present study, the cytotoxicity, mutagenicity and mutational spectrum at hprt were determined after EB-exposure of human TK6 lymphoblastoid cells (TK6 cells). EB was cytotoxic at concentrations ranging from 200 to 1000 microM x 24 h; at 400 microM x 24 h, the cell survival relative to unexposed controls was approximately 10%. Exposure of TK6 cells to EB (400 microM x 24 h) resulted in a 5-9-fold increase in the hprt mutant frequency. Molecular characterization of EB-induced hprt mutants indicated that 78% of the mutations at hprt were single base substitutions. A significant (P < 0.05) increase in A:T-->T:A transversions was observed compared with spontaneous hprt mutants isolated during these studies. All of the A:T-->T:A transversions in EB-induced mutants occurred with the A in the non-transcribed strand. These data indicate that a primary mode of genotoxicity induced by EB in human TK6 cells is the induction of single base substitutions.

2 August 2023 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Open access
SSStephanie L. Smith-Roe
Stephanie L. Smith-Roe
CHCheryl A. Hobbs
Cheryl A. Hobbs
VHVictoria Hull
Victoria Hull
JAJ. Todd Auman
J. Todd Auman
LRLeslie Recio
Leslie Recio
KWKristine Witt
Kristine Witt
Duplex sequencing (DS) is an error-corrected next-generation sequencing method in which molecular barcodes informatically link PCR-copies back to their source DNA strands, enabling computational removal of errors in consensus sequences. The resulting background of less than one artifactual mutation per 107 nucleotides allows for direct detection of somatic mutations. TwinStrand Biosciences, Inc. has developed a DS-based mutagenesis assay to sample the rat genome, which can be applied to genetic toxicity testing. To evaluate this assay for early detection of mutagenesis, a time-course study was conducted using male Hsd:Sprague Dawley SD rats (3 per group) administered a single dose of 40 mg/kg N-ethyl-N-nitrosourea (ENU) via gavage, with mutation frequency (MF) and spectrum analyzed in stomach, bone marrow, blood, and liver tissues at 3 h, 24 h, 7 d, and 28 d post-exposure. Significant increases in MF were observed in ENU-exposed rats as early as 24 h for stomach (site of contact) and bone marrow (a highly proliferative tissue) and at 7 d for liver and blood. The canonical, mutational signature of ENU was established by 7 d post-exposure in all four tissues. Interlaboratory analysis of a subset of samples from different tissues and time points demonstrated remarkable reproducibility for both MF and spectrum. These results demonstrate that MF and spectrum can be evaluated successfully by directly sequencing targeted regions of DNA obtained from various tissues⁠, a considerable advancement compared to currently used in vivo gene mutation assays.

8 November 2025 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
CYCarole L. Yauk
Carole L. Yauk
ALAnthony M. Lynch
Anthony M. Lynch
VDVasily N. Dobrovolsky
Vasily N. Dobrovolsky
MSMaik Schuler
Maik Schuler
SSStephanie L. Smith-Roe
Stephanie L. Smith-Roe
FMFrancesco Marchetti
Francesco Marchetti
Error-corrected sequencing (ECS) is a transformative method for in vivo mutagenicity assessment, enabling direct, highly sensitive measurement of mutation frequency and spectrum. ECS addresses key limitations of the transgenic rodent (TGR) assay, including lack of integration into standard toxicity studies, restricted model availability, and limited alignment with the 3R principles. To support regulatory acceptance, an expert workgroup of the International Workshops on Genotoxicity Testing (IWGT) reviewed ECS technologies and developed consensus recommendations for its inclusion into Organisation for Economic Co-operation and Development (OECD) test guidelines. The working group agreed that ECS: produces results that are concordant with validated TGR assays; can be incorporated into standard ≥28-day repeat-dose toxicity studies; and, data interpretation should be based on overall mutation frequency compared with concurrent vehicle controls. The working group emphasized harmonized data reporting aligned with OECD principles and endorsed study designs that enable quantitative risk assessment. Overall, the working group agreed that ECS offers a significant advancement over current mutagenicity assays by enabling the use of diverse models beyond conventional TGR systems described in OECD test guideline 488. The working group fully supports the application of ECS to generate in vivo mutagenicity data for regulatory submissions and recommends its inclusion in future OECD test guidelines.

26 October 2023 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Closed access
LRLeslie Recio
Leslie Recio
JFJasmine Fowler
Jasmine Fowler
LMLincoln Martin
Lincoln Martin
CSCarol Swartz
Carol Swartz

15 September 2025 in Frontiers in Toxicology
Verified
Journal Article
Open access
PDF file
ABA. Rasim Barutcu
A. Rasim Barutcu
NBNimisha Bhattarai
Nimisha Bhattarai
RSRaymond Samuel
Raymond Samuel
JSJamie Scaglione
Jamie Scaglione
LRLeslie Recio
Leslie Recio
Introduction: Human metabolically competent HepaRG™ (HepaRG) cells have been developed as a human-relevant New Approach Methodology (NAM) in genetic toxicology, providing a non-animal alternative to rodent-based mutagenicity testing following a positive Ames test. Error-corrected next-generation sequencing (ecNGS) offers improved sensitivity, specificity, and mechanistic insight in genotoxicity and mutagenicity assessment.Methods: We applied duplex sequencing, an ecNGS approach, to quantify chemically induced point mutations in metabolically competent HepaRG cells. Cells were exposed to a diverse panel of genotoxic agents, including ethyl methanesulfonate (EMS), N-ethyl-N-nitrosourea (ENU), benzo[a]pyrene (BAP), cisplatin, cyclophosphamide, and etoposide. Mutation frequency, substitution patterns, and mutational signatures were analyzed, and results were compared with complementary cytogenetic endpoints.Results: Duplex sequencing detected dose-responsive increases in mutation frequency for ENU and EMS, with distinct substitution patterns consistent with alkylating mechanisms. BAP and cisplatin induced modest increases in mutation frequency and C>A-enriched spectra, while cyclophosphamide yielded minimal mutagenicity under the tested conditions. Etoposide triggered strong cytogenetic responses without increasing point mutations, consistent with its clastogenic mode of action. COSMIC mutational signature analysis revealed modest enrichment of SBS4 (BAP), SBS11 (EMS), and SBS31/32 (cisplatin), supporting the mechanistic relevance of the model.Discussion: These findings demonstrate the reproducibility and specificity of ecNGS for detecting low-frequency point mutations and characterizing mutational mechanisms. When combined with complementary cytogenetic assays, duplex sequencing enables a more complete and human-relevant evaluation of genotoxic potential. This study supports the integration of ecNGS into next-generation genotoxicity testing strategies as a NAM for regulatory decision-making.

30 July 2024 in Toxicology Mechanisms and Methods
Verified
Journal Article
Open access
LRLeslie Recio
Leslie Recio
RSRaymond Samuel
Raymond Samuel
SESusan A. Elmore
Susan A. Elmore
JSJamie Scaglione
Jamie Scaglione
New Approach Methodologies (NAMs) are being widely used to reduce, refine, and replace, animal use in studying toxicology. For respiratory toxicology, this includes in silico and in vitro alternatives using air:liquid interface (ALI) exposures to replace traditional in vivo inhalation studies. In previous studies using 1,3-dichloropropene (1,3-DCP), a 5-day 4 h repeat exposures of MucilAir (TM) nasal cell culture models caused, dose-dependent cytotoxicity, depletion of GSH, changes in differential gene expression and histopathological transitions in cellular morphology from pseudostratified columnar epithelium to squamous epithelium. In this report we attempted to extend these studies using 15-day 1,3-DCP 4 h exposures to using MucilAir (TM) nasal cultures as outlined by an US EPA recent task order (US EPA 2023). For the 15-day repeat exposure, there were severe histopathologic changes in the MucilAir (TM) nasal mock-treatment (air-only) VITROCELL (R) chamber controls compared to incubator controls preventing any further analysis. The histopathological transitions in cellular morphology from pseudostratified columnar epithelium to squamous epithelium observed in the air only control in this study and previously with 1,3-DCP in MucilAir (TM) nasal cultures is also a hallmark of chemically induced cytotoxic responses in vivo in the respiratory tract. Histopathology assessments of 3D respiratory tract models used in ALI exposures can provide the linkage between in vitro to in vivo outcomes as part of the validation efforts of ALI use in regulatory toxicology. This report indicates that importance of histopathological assessments of incubator and mock-treatment (air-only) controls from each ALI exposure experiment along with exposed cell based model.